Results 31 to 40 of about 35,228 (288)

Semi-Automated Computational Assessment of Cancer Organoid Viability Using Rapid Live-Cell Microscopy

Cancer Informatics, 2022
The creation of patient-derived cancer organoids represents a key advance in preclinical modeling and has recently been applied to a variety of human solid tumor types.
Joseph D Buehler, Cylaina E Bird, Milan R Savani, Lauren C Gattie, William H Hicks, Michael M Levitt, Mohamad El Shami, Kimmo J Hatanpaa, Timothy E Richardson, Samuel K McBrayer, Kalil G Abdullah   +10 more
doaj   +1 more source

Organoid-based drug screening reveals neddylation as therapeutic target for malignant rhabdoid tumors

Cell Reports, 2021
Summary: Malignant rhabdoid tumors (MRTs) represent one of the most aggressive childhood malignancies. No effective treatment options are available, and prognosis is, therefore, dismal.
Camilla Calandrini, Sander R. van Hooff, Irene Paassen, Dilara Ayyildiz, Sepide Derakhshan, M. Emmy M. Dolman, Karin P.S. Langenberg, Marieke van de Ven, Cecilia de Heus, Nalan Liv, Marcel Kool, Ronald R. de Krijger, Godelieve A.M. Tytgat, Marry M. van den Heuvel-Eibrink, Jan J. Molenaar, Jarno Drost   +15 more
doaj   +1 more source

Large variety in a panel of human colon cancer organoids in response to EZH2 inhibition [PDF]

, 2016
EZH2 inhibitors have gained great interest for their use as anti-cancer therapeutics. However, most research has focused on EZH2 mutant cancers and recently adverse effects of EZH2 inactivation have come to light.
Bounova, Gergana, Cornelissen-Steijger, Paulien, de Vries, Nienke, Koppens, Martijn A.J., Sansom, Owen J., van Lohuizen, Maarten, Wessels, Lodewyk F.A.   +6 more
core   +1 more source

The stress polarity signaling (SPS) pathway serves as a marker and a target in the leaky gut barrier: implications in aging and cancer. [PDF]

, 2020
The gut barrier separates trillions of microbes from the largest immune system in the body; when compromised, a "leaky" gut barrier fuels systemic inflammation, which hastens the progression of chronic diseases.
Das, Soumita, Foretz, Marc, Ghosh, Pradipta, Ibeawuchi, Stella-Rita, Lim, Blaze B, Mittal, Yash, Sahoo, Debashis, Sayed, Ibrahim M, Swanson, Lee, Viollet, Benoit   +9 more
core   +3 more sources

[Patient-derived tumor organoids (or tumoroid), a growing preclinical model for oncology].

Medecine sciences : M/S, 2022
La récente émergence des cultures d’organoïdes tumoraux, ou tumoroïdes, a permis d’enrichir le répertoire des modèles précliniques en oncologie. Très proches de la tumeur dont elles dérivent, ces microtumeurs offrent de nombreuses possibilités en termes de recherche fondamentale, telles que l’étude de la carcinogenèse ou de la chimioré-sistance, de ...
Thorel, Lucie, Florent, Romane, Perréard, Marion, Vincent, Audrey, Poulain, Laurent, Weiswald, Louis-Bastien   +5 more
openaire   +3 more sources

Targeting the tumor microenvironment in colorectal peritoneal metastases

, 2020
Peritoneal metastasis (PM) occurs in approximately one in four colorectal cancer (CRC) patients. The pathophysiology of colorectal PM remains poorly characterized. Also, the efficacy of current treatment modalities, including surgery and intraperitoneal (
Ceelen, Wim, De Wever, Olivier, Heriot, Alexander G., Narasimhan, Vignesh, Ramsay, Robert G.   +4 more
core   +1 more source

Widespread parainflammation in human cancer. [PDF]

, 2016
BackgroundChronic inflammation has been recognized as one of the hallmarks of cancer. We recently showed that parainflammation, a unique variant of inflammation between homeostasis and chronic inflammation, strongly promotes mouse gut tumorigenesis upon ...
Aran, Dvir, Ben-Neriah, Yinon, Biton, Moshe, Butte, Atul J, Hellman, Asaf, Lasry, Audrey, Pikarsky, Eli, Zinger, Adar   +7 more
core   +3 more sources

Patient‐derived organoids as a preclinical platform for precision medicine in colorectal cancer

Molecular Oncology, 2022
Patient‐derived organoids are being considered as models that can help guide personalized therapy through in vitro anticancer drug response evaluation. However, attempts to quantify in vitro drug responses in organoids and compare them with responses in ...
Young‐Won Cho, Dong‐Wook Min, Hwang‐Phill Kim, Yohan An, Sheehyun Kim, Jeonghwan Youk, Jaeyoung Chun, Jong Pil Im, Sang‐Hyun Song, Young Seok Ju, Sae‐Won Han, Kyu Joo Park, Tae‐You Kim   +12 more
doaj   +1 more source

Opportunities for organoids as new models of aging. [PDF]

, 2018
The biology of aging is challenging to study, particularly in humans. As a result, model organisms are used to approximate the physiological context of aging in humans. However, the best model organisms remain expensive and time-consuming to use.
Antonica, Arora, Astashkina, Auger, Aw, Azpurua, Barbero, Barkauskas, Barkauskas, Barker, Bartfeld, Behjati, Belmin, Ben-Ze’ev, Bhumiratana, Blau, Blokzijl, Brack, Broutier, Busuttil, Caron, Caughey, Cerchiari, Chambers, Chang, Chaudhuri, Choi, Cornacchia, Crabb, Danahay, Dekkers, Dos Santos, Dye, Eiraku, Elahy, Engevik, Freedman, Gao, Garbe, Gjorevski, Greider, Gullapalli, Hannum, Hansen, Hegab, Heintz, Hibiya, Hohwieler, Horvath, Htwe, Huch, Huch, Jennifer L. Hu, Jones, Jung, Karthaus, Kolesky, Koo, Kwong, Lang, Lee, Lee, Levental, Li, Li, Lindahl, Linnemann, Liu, Lozito, Lyons, López-Otín, L’Heureux, Madden, Marciniak, Mark A. LaBarge, Matsui, Mattison, McElwee, Meerwaldt, Mertens, Messner, Michael E. Todhunter, Miller, Moore, Moore, Morizane, Murrow, Myers, Nalapareddy, Nasto, Nelson, Nevalainen, Nguyen-Ngoc, Nicholas, Noguchi, Ootani, O’Brien, Pageon, Pang, Parrinello, Pauli, Phillip, Plaks, Pribluda, Qian, Raja, Rangarajan, Rodriguez-Teja, Ruan, Sancar, Sato, Schütte, Seok, Simian, Singh, Squires, Stampfer, Stearns-Reider, Stojadinovic, Sun, Takasato, Takebe, Tan, Tanos, Toda, Todhunter, Turco, Tzatzalos, van Vliet, Vanhooren, Vernetti, Verzijl, Villadsen, Villeda, Voytik-Harbin, Watson, Williams, Wilson, Workman, Wu, Wylie, Xiang, Yilmaz, Zev J. Gartner, Zhang, Zhang   +145 more
core   +2 more sources

Patient-derived tumor organoids mimic treatment-induced DNA damage response in glioblastoma. [PDF]

iScience
Glioblastoma (GB) is the most common primary malignant brain tumor, characterized by resistance to therapy. Despite aggressive treatment options, GB remains an incurable disease. Invasiveness and heterogeneity are key GB features that cannot be studied in preclinical in vitro models.
Majc B, Habič A, Malavolta M, Vittori M, Porčnik A, Bošnjak R, Mlakar J, Matjašič A, Zupan A, Vidmar MS, Turnšek TL, Sadikov A, Breznik B, Novak M.   +13 more
europepmc   +5 more sources